|
| | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 HB3721 Introduced 2/17/2023, by Rep. Terra Costa Howard SYNOPSIS AS INTRODUCED: |
| New Act | | 720 ILCS 570/102 | from Ch. 56 1/2, par. 1102 |
|
Creates the Naturopathic Medical Practice Act. Provides for the licensure of naturopathic physicians. Creates the Naturopathic Physician Medical Board. Provides that the Board shall oversee the licensure of naturopathic physicians and matters relating to training and licensure of naturopathic physicians. Provides for membership of the Board and duties of the Board. Contains provisions concerning: definitions; qualifications for licensure; approval of naturopathic medical educational programs; display of license; scope of practice; referral requirements; prohibited conduct by licenses; exemptions from the Act; title protection; license expiration, renewal, denial, revocation, and continuing education; grounds for disciplinary action; investigation, notice, hearing; record of proceedings; and confidentiality. Amends the Illinois Controlled Substances Act. Adds internal references to naturopathic physicians in the definitions of "practitioner", "prescriber", and "prescription". Effective immediately.
|
| |
| | A BILL FOR |
|
|
| | HB3721 | | LRB103 30237 AMQ 56665 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 1. Short title. This Act may be cited as the |
5 | | Naturopathic Medical Practice Act. |
6 | | Section 5. Purpose and findings. The practice of |
7 | | naturopathic medicine in the State is declared to affect the |
8 | | public health, safety, and welfare and to be subject to |
9 | | regulation and control in the public interest. It is further |
10 | | declared to be a matter of public interest that naturopathic |
11 | | physicians and the practice of naturopathic medicine, as |
12 | | defined in this Act, merit the confidence of the public, that |
13 | | only qualified persons be authorized to practice naturopathic |
14 | | medicine in the State, and that no person shall practice |
15 | | naturopathic medicine without a valid existing license to do |
16 | | so.
|
17 | | The State is facing an unprecedented physician shortage in |
18 | | urban counties and an even higher shortage in rural counties. |
19 | | The COVID-19 pandemic increased that shortage exponentially. |
20 | | Naturopathic physicians with a proper scope of practice can |
21 | | help fill this void.
|
22 | | The General Assembly recognizes that naturopathic |
23 | | physicians comprise a distinct health care profession that |
|
| | HB3721 | - 2 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | affects the public health, safety, and welfare and that |
2 | | licensure of naturopathic physicians will increase freedom of |
3 | | choice in health care and help address the physician shortage |
4 | | in the State. This Act shall be liberally construed to best |
5 | | carry out these subjects and purposes.
|
6 | | Section 10. Definitions. In this Act:
|
7 | | "Approved naturopathic medical educational program" means |
8 | | an educational program that the Board has approved as meeting |
9 | | the requirements of Section 20 of this Act that prepares |
10 | | naturopathic physicians for the practice of naturopathic |
11 | | medicine.
|
12 | | "Association" means an entity that is approved by the |
13 | | American Association of Naturopathic Physicians, which entity |
14 | | represents the interests of naturopathic physicians in this |
15 | | State.
|
16 | | "Board" means the Naturopathic Physician Medical Board |
17 | | established pursuant to Section 55 of this Act.
|
18 | | "Clinical laboratory procedure" means the use of |
19 | | venipuncture consistent with naturopathic medical practice, |
20 | | commonly used diagnostic modalities consistent with |
21 | | naturopathic practice, the recording of a patient's health |
22 | | history, physical examination, ordering and interpretation of |
23 | | radiographic diagnostics and other standard imaging and |
24 | | examination of body orifices, excluding endoscopy and |
25 | | colonoscopy. "Clinical laboratory procedure" includes the |
|
| | HB3721 | - 3 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | practice of obtaining samples of human tissues, except |
2 | | surgical excision beyond surgical excision that is authorized |
3 | | as a minor office procedure. |
4 | | "Drug" has the same meaning as set forth in Section 102 of |
5 | | the Illinois Controlled Substances Act.
|
6 | | "Homeopathic medicine" means a system of medicine based on |
7 | | the use of infinitesimal doses of substances capable of |
8 | | producing symptoms similar to those of the disease treated, as |
9 | | listed in the Homeopathic Pharmacopoeia of the United States.
|
10 | | "Hygiene" means the use of preventive techniques, |
11 | | including personal hygiene for asepsis, public health, and |
12 | | safety.
|
13 | | "Laboratory examination" means:
|
14 | | (1) phlebotomy;
|
15 | | (2) a clinical laboratory procedure;
|
16 | | (3) an orificial examination;
|
17 | | (4) a physiological function test; and
|
18 | | (5) a screening or test that is consistent with |
19 | | naturopathic education and training.
|
20 | | "Legend drug" has the same meaning as set forth in Section |
21 | | 3.23 of the Illinois Food, Drug and Cosmetic Act.
|
22 | | "License" means a license issued by the Board to an |
23 | | individual pursuant to this Act and rules authorizing that |
24 | | individual to practice naturopathic medicine in this State.
|
25 | | "Licensee" means a naturopathic physician licensed by the |
26 | | Board to practice naturopathic medicine in this State.
|
|
| | HB3721 | - 4 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | "Minor office procedure" means minor surgical care and |
2 | | procedures, including:
|
3 | | (1) surgical care incidental to superficial |
4 | | laceration, lesion, or abrasion, excluding surgical care |
5 | | to treat a lesion suspected of malignancy;
|
6 | | (2) the removal of foreign bodies located in |
7 | | superficial structures, excluding the globe of the eye; |
8 | | (3) trigger point therapy;
|
9 | | (4) dermal stimulation;
|
10 | | (5) allergy testing and treatment; and
|
11 | | (6) the use of antiseptics and topical or local |
12 | | anesthetics.
|
13 | | "Naturopathic medicine" means:
|
14 | | (1) a system of health care for the prevention, |
15 | | diagnosis and treatment of human health conditions, |
16 | | injury, and disease;
|
17 | | (2) the promotion or restoration of health; and
|
18 | | (3) the support and stimulation of a patient's |
19 | | inherent self-healing processes through patient education |
20 | | and the use of naturopathic therapies and therapeutic |
21 | | substances.
|
22 | | "Naturopathic physical medicine" means the use of one or |
23 | | more of the following physical agents in a manner consistent |
24 | | with naturopathic medical practice on a part or the whole of |
25 | | the body, by hand or by mechanical means, in the resolution of |
26 | | a human ailment or conditions:
|
|
| | HB3721 | - 5 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (1) air;
|
2 | | (2) water;
|
3 | | (3) heat;
|
4 | | (4) cold;
|
5 | | (5) sound;
|
6 | | (6) light;
|
7 | | (7) electromagnetism;
|
8 | | (8) colon hydrotherapy;
|
9 | | (9) soft tissue therapy;
|
10 | | (10) joint mobilization;
|
11 | | (11) therapeutic exercise; or
|
12 | | (12) naturopathic manipulation.
|
13 | | "Naturopathic physician" means an individual licensed |
14 | | pursuant to this Act as a naturopathic physician to practice |
15 | | naturopathic medicine in this State.
|
16 | | "Naturopathic therapy" means the use of:
|
17 | | (1) naturopathic physical medicine;
|
18 | | (2) suggestion;
|
19 | | (3) hygiene;
|
20 | | (4) a therapeutic substance;
|
21 | | (5) nutrition and food science;
|
22 | | (6) homeopathic medicine;
|
23 | | (7) a clinical laboratory procedure; or
|
24 | | (8) a minor office procedure.
|
25 | | "Nutrition and food science" means the prevention and |
26 | | treatment of disease or other human conditions through the use |
|
| | HB3721 | - 6 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | of food, water, herbs, roots, bark, or natural food elements.
|
2 | | "Prescription" has the same meaning as set forth in |
3 | | Section 3 of the Pharmacy Practice Act.
|
4 | | "Professional examination" means a competency based |
5 | | naturopathic physician licensing examination as determined by |
6 | | Department rule. |
7 | | "Suggestion" means a technique using:
|
8 | | (1) biofeedback;
|
9 | | (2) hypnosis;
|
10 | | (3) health education; or
|
11 | | (4) health counseling.
|
12 | | "Telehealth" or "telepractice" means the delivery of |
13 | | services under this Act by using electronic communication, |
14 | | information technologies, or other means between an individual |
15 | | licensed under this Act in one location and a patient or client |
16 | | in another location, with or without an intervening healthcare |
17 | | provider. "Telehealth" or "telepractice" includes direct, |
18 | | interactive patient encounters, asynchronous |
19 | | store-and-forward technologies, and remote monitoring. |
20 | | Telehealth or telepractice is not prohibited under this Act |
21 | | provided that the provision of telehealth or telepractice |
22 | | services is appropriate for the client and the level of care |
23 | | provided meets the required level of care for that client. |
24 | | Individuals providing services regulated by this Act via |
25 | | telepractice shall comply with and are subject to all |
26 | | licensing and disciplinary provisions of this Act. |
|
| | HB3721 | - 7 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | "Therapeutic substance" means any of the following |
2 | | exemplified in a standard naturopathic medical text, journal, |
3 | | or pharmacopeia:
|
4 | | (1) a vitamin;
|
5 | | (2) a mineral;
|
6 | | (3) a nutraceutical;
|
7 | | (4) a botanical medicine;
|
8 | | (5) oxygen;
|
9 | | (6) a homeopathic medicine;
|
10 | | (7) a hormone;
|
11 | | (8) a hormonal or pharmaceutical contraceptive device; |
12 | | or
|
13 | | (9) other physiologic substance.
|
14 | | Section 15. Qualifications for licensure. The Board shall |
15 | | license an applicant who:
|
16 | | (1) submits, in accordance with rules of the |
17 | | Department, the following items to the Board:
|
18 | | (A) an application for licensure designed and |
19 | | approved by the Board and submitted in accordance with |
20 | | rules of the Department;
|
21 | | (B) an application fee submitted in an amount and |
22 | | manner established by rules of the Department;
|
23 | | (C) evidence that the applicant has graduated from |
24 | | a Council on Naturopathic Medical Education or an |
25 | | equivalent federally recognized accrediting body, |
|
| | HB3721 | - 8 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | approved naturopathic medical education program;
|
2 | | (D) evidence that the applicant has passed a |
3 | | professional examination authorized by rule of the |
4 | | Department and administered by the North American |
5 | | Board of Naturopathic Examiners or its successor;
|
6 | | (E) evidence that the applicant has passed a |
7 | | pharmacy examination authorized by rules of the |
8 | | Department and administered by the North American |
9 | | Board of Naturopathic Examiners or its successor;
|
10 | | (F) evidence that the applicant has passed a minor |
11 | | surgery examination authorized by rules of the |
12 | | Department and administered by the North American |
13 | | Board of Naturopathic Examiners or its successor; and
|
14 | | (G) evidence of professional liability insurance |
15 | | with policy limits not less than prescribed by the |
16 | | Department;
|
17 | | (2) is determined by the Board to be physically and |
18 | | mentally capable of safely practicing naturopathic |
19 | | medicine with or without reasonable accommodation; and
|
20 | | (3) has not had a license to practice naturopathic |
21 | | medicine or other health care license, registration, or |
22 | | certificate refused, revoked, or suspended by any other |
23 | | jurisdiction for reasons that relate to the applicant's |
24 | | ability to skillfully and safely practice naturopathic |
25 | | medicine unless that license, registration, or |
26 | | certification has been restored to good standing by that |
|
| | HB3721 | - 9 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | jurisdiction.
|
2 | | Section 20. Approved naturopathic medical educational |
3 | | program. The Department shall establish, by rule, guidelines |
4 | | for an approved naturopathic medical educational program, |
5 | | which guidelines shall meet the following requirements and the |
6 | | Department's specifications for the education of naturopathic |
7 | | physicians. The approved naturopathic medical educational |
8 | | program shall:
|
9 | | (1) offer graduate-level, full-time didactic and |
10 | | supervised clinical training;
|
11 | | (2) be accredited, or have achieved candidacy status |
12 | | for accreditation, by the Council on Naturopathic Medical |
13 | | Education or an equivalent federally recognized |
14 | | accrediting body for naturopathic medical programs that is |
15 | | also recognized by the Department; and
|
16 | | (3) be conducted by an institution of higher |
17 | | education, or a division of an institution of higher |
18 | | education, that:
|
19 | | (A) is accredited or is a candidate for |
20 | | accreditation by a regional or national institutional |
21 | | accrediting agency recognized by the United States |
22 | | Secretary of Education or a diploma-granting, |
23 | | degree-equivalent college or university; or
|
24 | | (B) meets equivalent standards for recognition of |
25 | | accreditation established by rules of the Department |
|
| | HB3721 | - 10 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | for medical education programs offered in Canada.
|
2 | | Section 25. Display of license. A licensee shall display |
3 | | the licensee's license in the licensee's place of business in |
4 | | a location clearly visible to the licensee's patients and |
5 | | shall also display evidence of the licensee having completed |
6 | | an approved naturopathic medical educational program. |
7 | | Section 30. Scope of practice. |
8 | | (a) A licensee may practice naturopathic medicine to |
9 | | provide primary care in alignment with naturopathic medical |
10 | | education to:
|
11 | | (1) perform physical examinations;
|
12 | | (2) order laboratory examinations;
|
13 | | (3) order diagnostic imaging studies;
|
14 | | (4) interpret the results of laboratory examinations |
15 | | for diagnostic purposes;
|
16 | | (5) order and, based on a radiologist's report, take |
17 | | action on diagnostic imaging studies in a manner |
18 | | consistent with naturopathic training;
|
19 | | (6) prescribe, administer, dispense, and order food, |
20 | | extracts of food, nutraceuticals, vitamins, amino acids, |
21 | | minerals, enzymes, botanicals and their extracts, |
22 | | botanical medicines, homeopathic medicines, dietary |
23 | | supplements, and nonprescription drugs as defined by the |
24 | | Federal Food, Drug, and Cosmetic Act;
|
|
| | HB3721 | - 11 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (7) dispense and order all legend drugs in the regular |
2 | | course of practicing naturopathic medicine. The dispensing |
3 | | of such legend drugs shall be the personal act of the |
4 | | person licensed under this Act and may not be delegated to |
5 | | any other person not licensed under this Act or the |
6 | | Pharmacy Practice Act unless such delegated dispensing |
7 | | functions are under the direct supervision of the |
8 | | physician authorized to dispense legend drugs. Except when |
9 | | dispensing manufacturers' samples or other legend drugs in |
10 | | a maximum 72 hour supply, persons licensed under this Act |
11 | | shall maintain a book or file of prescriptions as required |
12 | | in the Pharmacy Practice Act. Any person licensed under |
13 | | this Act who dispenses any drug or medicine shall dispense |
14 | | such drug or medicine in good faith and shall affix to the |
15 | | box, bottle, vessel or package containing the same a label |
16 | | indicating (i) the date on which such drug or medicine is |
17 | | dispensed; (ii) the name of the patient; (iii) the last |
18 | | name of the person dispensing such drug or medicine; (iv) |
19 | | the directions for use thereof; and (v) the proprietary |
20 | | name or names or, if there are none, the established name |
21 | | or names of the drug or medicine, the dosage and quantity, |
22 | | except as otherwise authorized by regulation of the |
23 | | Department; |
24 | | (8) prescribe, administer, dispense, and order all |
25 | | drugs within Schedules II-V of the Controlled Substances |
26 | | Act; |
|
| | HB3721 | - 12 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (9) use routes of administration that include oral, |
2 | | nasal, auricular, ocular, rectal, vaginal, transdermal, |
3 | | intradermal, subcutaneous, intravenous, intra-articular, |
4 | | and intramuscular consistent with the education and |
5 | | training of a naturopathic physician;
|
6 | | (10) administer intramuscular, intravenous, |
7 | | subcutaneous, intra-articular and intradermal injections |
8 | | of vaccines; |
9 | | (11) administer intramuscular, intravenous, |
10 | | subcutaneous, intra-articular and intradermal injections |
11 | | of substances appropriate to naturopathic medicine;
|
12 | | (12) perform naturopathic physical medicine;
|
13 | | (13) employ the use of naturopathic therapy;
|
14 | | (14) use therapeutic devices, barrier contraception, |
15 | | intrauterine devices, hormonal and pharmaceutical |
16 | | contraception, and durable medical equipment; or
|
17 | | (15) perform minor office procedures.
|
18 | | (b) A licensee may practice naturopathic medicine via |
19 | | telehealth services. |
20 | | Section 35. Referral requirement. A licensee shall refer |
21 | | to a physician licensed to practice medicine in all of its |
22 | | branches under the Medical Practice Act of 1987 or an advanced |
23 | | practice registered nurse licensed under the Nurse Practice |
24 | | Act any patient whose medical condition is determined, at the |
25 | | time of evaluation or treatment, to be beyond the scope of |
|
| | HB3721 | - 13 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | practice of the licensee. |
2 | | Section 40. Prohibitions. A licensee shall not:
|
3 | | (1) perform surgery outside of the scope of minor |
4 | | office procedures permitted in the employment of |
5 | | naturopathic therapy;
|
6 | | (2) use general or spinal anesthetics;
|
7 | | (3) administer ionizing radioactive substances for |
8 | | therapeutic purposes;
|
9 | | (4) perform a surgical procedure using a laser device;
|
10 | | (5) perform a surgical procedure involving any of the |
11 | | following areas of the body that extend beyond superficial |
12 | | tissue:
|
13 | | (A) eyes;
|
14 | | (B) ears;
|
15 | | (C) tendons;
|
16 | | (D) nerves;
|
17 | | (E) veins; or
|
18 | | (F) arteries;
|
19 | | (6) perform a surgical abortion;
|
20 | | (7) treat any lesion suspected of malignancy or |
21 | | requiring surgical removal; or
|
22 | | (8) perform acupuncture.
|
23 | | Section 45. Exemptions. Nothing in this Act shall be |
24 | | construed to prohibit or to restrict:
|
|
| | HB3721 | - 14 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (1) the practice of a health care profession by an |
2 | | individual who is licensed, certified, or registered under |
3 | | other laws of this State and who is performing services |
4 | | within the individual's authorized scope of practice;
|
5 | | (2) the practice of naturopathic medicine by a student |
6 | | enrolled in an approved naturopathic medical educational |
7 | | program if the practice of naturopathic medicine by a |
8 | | student is performed pursuant to a course of instruction |
9 | | or an assignment from an instructor at an accredited |
10 | | university or college by an instructor duly licensed as a |
11 | | health care provider in the State;
|
12 | | (3) any person who sells a vitamin or herb from |
13 | | providing information about the vitamin or herb;
|
14 | | (4) the practice of naturopathic medicine by persons |
15 | | who are licensed to practice in any other state or |
16 | | district in the United States and who enter this State to |
17 | | consult with a naturopathic physician of this State if the |
18 | | consultation is limited to an examination or |
19 | | recommendation; or
|
20 | | (5) any person or practitioner who is not licensed as |
21 | | a naturopathic physician from recommending ayurvedic |
22 | | medicine, herbal remedies, nutritional advice, homeopathy, |
23 | | or other therapy that is within the scope of practice of |
24 | | naturopathic medicine; however, the person or practitioner |
25 | | shall not:
|
26 | | (A) use a title protected pursuant to Section 50 |
|
| | HB3721 | - 15 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | of this Act;
|
2 | | (B) represent or assume the character or |
3 | | appearance of a licensee; or
|
4 | | (C) otherwise use a name, title, or other |
5 | | designation that indicates or implies that the person |
6 | | is a licensee.
|
7 | | Section 50. Protected titles.
|
8 | | (a) A licensee shall use the title "naturopathic |
9 | | physician", "naturopathic doctor", or "naturopathic medical |
10 | | doctor" and the recognized abbreviations "N.D." and "N.M.D.".
|
11 | | (b) A licensee has the exclusive right to use the |
12 | | following terms in reference to the licensee's self:
|
13 | | (1) "naturopathic physician";
|
14 | | (2) "naturopathic doctor";
|
15 | | (3) "naturopathic medical doctor";
|
16 | | (4) "doctor of naturopathic medicine";
|
17 | | (5) "doctor of naturopathy";
|
18 | | (6) "naturopath";
|
19 | | (7) "N.D.";
|
20 | | (8) "ND";
|
21 | | (9) "NMD"; and
|
22 | | (10) "N.M.D.".
|
23 | | (c) An individual represents the individual's self to be a |
24 | | naturopathic physician or a naturopathic doctor when the |
25 | | individual uses or adopts any of the following terms in |
|
| | HB3721 | - 16 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | reference to the individual's self:
|
2 | | (1) "naturopathic physician";
|
3 | | (2) "naturopathic doctor";
|
4 | | (3) "naturopathic medical doctor";
|
5 | | (4) "doctor of naturopathic medicine";
|
6 | | (5) "doctor of naturopathy";
|
7 | | (6) "naturopath";
|
8 | | (7) "N.D.";
|
9 | | (8) "ND";
|
10 | | (9) "NMD"; and
|
11 | | (10) "N.M.D.".
|
12 | | (d) An individual shall not represent the individual's |
13 | | self to the public as a naturopathic physician, naturopathic |
14 | | doctor, naturopathic medical doctor, a doctor of naturopathic |
15 | | medicine, a doctor of naturopathy, or as being otherwise |
16 | | authorized to practice naturopathic medicine in this State, |
17 | | unless the individual is a licensee.
|
18 | | Section 55. Naturopathic Physician Medical Board.
|
19 | | (a) The Naturopathic Physician Medical Board shall |
20 | | oversee:
|
21 | | (1) licensure of naturopathic physicians; and
|
22 | | (2) matters relating to training and licensure of |
23 | | naturopathic physicians.
|
24 | | (b) Within 180 days after the effective date of this Act, |
25 | | the Governor shall appoint an initial Board consisting of 2 |
|
| | HB3721 | - 17 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | members for terms of 4 years each, 3 members for terms of 3 |
2 | | years each, and 4 members for terms of 2 years each. The |
3 | | initial Board shall consist of the following voting members:
|
4 | | (1) five licensed naturopathic physicians who are |
5 | | residents of the State;
|
6 | | (2) two practicing physicians licensed to practice |
7 | | medicine in all of its branches; and
|
8 | | (3) two public members who are residents of this |
9 | | State, who are not, and never have been, a licensed health |
10 | | care practitioner, and who do not have an interest in |
11 | | naturopathic education, naturopathic medicine, or |
12 | | naturopathic business or practice.
|
13 | | Members of the Board may be recommended to the Governor by |
14 | | the Illinois Association of Naturopathic Physicians. |
15 | | (c) As the terms of the initial Board members expire, the |
16 | | Governor shall appoint successors for terms of 4 years each as |
17 | | follows:
|
18 | | (1) five naturopathic physicians licensed pursuant to |
19 | | this Act;
|
20 | | (2) two practicing physicians licensed to practice |
21 | | medicine in all of its branches with experience working |
22 | | with naturopathic physicians; and
|
23 | | (3) two public members that are residents of this |
24 | | State who are not, and never have been, a licensed health |
25 | | care practitioner and who do not have an interest in |
26 | | naturopathic education, naturopathic medicine or |
|
| | HB3721 | - 18 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | naturopathic business or practice.
|
2 | | (d) Within 30 days after the Board is established, the |
3 | | Board shall call the first meeting, at which meeting members |
4 | | shall elect a chair. The Board may hold meetings at the call of |
5 | | the chair or at the written request of any 2 members of the |
6 | | Board.
|
7 | | (e) Vacancies on the Board shall be filled from a list of |
8 | | not fewer than 3 candidates.
|
9 | | (f) A majority of the Board shall constitute a quorum.
|
10 | | (g) Members of the Board shall serve without compensation |
11 | | but may, at the discretion of the Board, be reimbursed for |
12 | | their expenses incurred in performing their duties. |
13 | | (h) The Department of Financial and Professional |
14 | | Regulation shall provide administrative and other support to |
15 | | the Board. |
16 | | Section 60. Board duties. The Board shall have the |
17 | | following duties:
|
18 | | (1) regulating the licensure of naturopathic |
19 | | physicians and determining the hours of continuing |
20 | | education units required for maintaining licensure as a |
21 | | naturopathic physician;
|
22 | | (2) prescribing the manner in which records of |
23 | | examinations and treatments shall be kept and maintained;
|
24 | | (3) establishing standards for professional |
25 | | responsibility and conduct;
|
|
| | HB3721 | - 19 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (4) identifying disciplinary actions and circumstances |
2 | | that require disciplinary action;
|
3 | | (5) developing a means to provide information to all |
4 | | licensees in this State;
|
5 | | (6) providing for the investigation of complaints |
6 | | against licensees or persons holding themselves out as |
7 | | naturopathic physicians in this State;
|
8 | | (7) providing for the publication of information for |
9 | | the public about licensees and the practice of |
10 | | naturopathic medicine in this State;
|
11 | | (8) providing for an orderly process for reinstatement |
12 | | of a license;
|
13 | | (9) establishing criteria for advertising or |
14 | | promotional materials;
|
15 | | (10) establishing continuing education hours and |
16 | | content;
|
17 | | (11) establishing procedures and standards for |
18 | | reviewing licensing examination scores; and
|
19 | | (12) establishing procedures for reviewing transcripts |
20 | | demonstrating completion of the approved naturopathic |
21 | | medical educational program;
|
22 | | (13) establishing and maintaining a list of |
23 | | naturopathic medical education programs that meet the |
24 | | requirements of Section 20;
|
25 | | (14) establishing the requirements for issuance and |
26 | | renewal of licenses; and
|
|
| | HB3721 | - 20 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (15) any other matter necessary to implement this Act.
|
2 | | Section 65. License expiration, renewal, denial, |
3 | | revocation, and continuing education.
|
4 | | (a) A license issued or renewed pursuant to this Act shall |
5 | | expire in a time frame determined by rule by the Department.
|
6 | | (b) The Board may renew the license of any licensee who, |
7 | | upon the expiration of the licensee's license:
|
8 | | (1) has submitted an application for renewal;
|
9 | | (2) has paid the renewal fee established by rules of |
10 | | the Department;
|
11 | | (3) meets the qualifications for licensure set forth |
12 | | in this Act and rules of the Department; and
|
13 | | (4) meets the continuing education requirements |
14 | | established by the Board.
|
15 | | (c) If the Board intends to refuse to issue or renew, |
16 | | revoke, or suspend a license, the Department shall grant the |
17 | | applicant or licensee an opportunity for a hearing.
|
18 | | Section 70. Grounds for disciplinary action. |
19 | | (a) The Department may refuse to issue or to renew, or may |
20 | | revoke, suspend, place on probation, reprimand, or take other |
21 | | disciplinary or non-disciplinary action with regard to any |
22 | | license issued under this Act as the Department may deem |
23 | | proper, including the issuance of fines not to exceed $10,000 |
24 | | for each violation, for any one or combination of the |
|
| | HB3721 | - 21 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | following causes: |
2 | | (1) material misstatement in furnishing information to |
3 | | the Department; |
4 | | (2) violations of this Act, or the rules adopted
under |
5 | | this Act; |
6 | | (3) conviction by plea of guilty or nolo contendere,
|
7 | | finding of guilt, jury verdict, or entry of judgment or |
8 | | sentencing, including, but not limited to, convictions, |
9 | | preceding sentences of supervision, conditional discharge, |
10 | | or first offender probation, under the laws of any |
11 | | jurisdiction of the United States that is: (i) a felony; |
12 | | or (ii) a misdemeanor, an essential element of which is |
13 | | dishonesty, or that is directly related to the practice of |
14 | | the profession; |
15 | | (4) making any misrepresentation for the purpose of
|
16 | | obtaining licenses; |
17 | | (5) professional incompetence; |
18 | | (6) aiding or assisting another person in violating
|
19 | | any provision of this Act or its rules; |
20 | | (7) failing, within 60 days, to provide information
in |
21 | | response to a written request made by the Department; |
22 | | (8) engaging in dishonorable, unethical, or
|
23 | | unprofessional conduct, as defined by rule, of a character |
24 | | likely to deceive, defraud, or harm the public.
|
25 | | (9) habitual or excessive use or addiction to
alcohol, |
26 | | narcotics, stimulants, or any other chemical agent or drug |
|
| | HB3721 | - 22 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | that results in a naturopathic physician's inability to |
2 | | practice with reasonable judgment, skill, or safety; |
3 | | (10) discipline by another U.S. jurisdiction or
|
4 | | foreign nation, if at least one of the grounds for |
5 | | discipline is the same or substantially equivalent to |
6 | | those set forth in this Section; |
7 | | (11) directly or indirectly giving to or receiving
|
8 | | from any person, firm, corporation, partnership, or |
9 | | association any fee, commission, rebate or other form of |
10 | | compensation for any professional services not actually or |
11 | | personally rendered. Nothing in this paragraph (11) |
12 | | affects any bona fide independent contractor or employment |
13 | | arrangements, which may include provisions for |
14 | | compensation, health insurance, pension, or other |
15 | | employment benefits, with persons or entities authorized |
16 | | under this Act for the provision of services within the |
17 | | scope of the licensee's practice under this Act; |
18 | | (12) abandonment of a patient; |
19 | | (13) willfully making or filing false records or
|
20 | | reports in the individual's practice, including, but not |
21 | | limited to, false records filed with state agencies or |
22 | | departments; |
23 | | (14) physical illness, or mental illness or
impairment |
24 | | that results in the inability to practice the profession |
25 | | with reasonable judgment, skill, or safety, including, but |
26 | | not limited to, deterioration through the aging process or |
|
| | HB3721 | - 23 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | loss of motor skill; |
2 | | (15) being named as a perpetrator in an indicated
|
3 | | report by the Department of Children and Family Services |
4 | | under the Abused and Neglected Child Reporting Act, and |
5 | | upon proof by clear and convincing evidence that the |
6 | | licensee has caused a child to be an abused child or |
7 | | neglected child as defined in the Abused and Neglected |
8 | | Child Reporting Act; |
9 | | (16) gross negligence resulting in permanent injury
or |
10 | | death of a patient; |
11 | | (17) employment of fraud, deception or any unlawful
|
12 | | means in applying for or securing a license under this |
13 | | Act; |
14 | | (18) immoral conduct in the commission of any act,
|
15 | | such as sexual abuse, sexual misconduct, or sexual |
16 | | exploitation related to the licensee's practice; |
17 | | (19) practicing under a false or assumed name, except
|
18 | | as provided by law; |
19 | | (20) making a false or misleading statement regarding
|
20 | | the licensee's skill or the efficacy or value of the |
21 | | treatment or remedy prescribed by the licensee in the |
22 | | course of treatment; |
23 | | (21) allowing another person to use the licensee's
|
24 | | license to practice; |
25 | | (22) prescribing, selling, administering,
|
26 | | distributing, giving, or self-administering a drug |
|
| | HB3721 | - 24 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | classified as a controlled substance; |
2 | | (23) a pattern of practice or other behavior that
|
3 | | demonstrates incapacity or incompetence to practice under |
4 | | this Act; |
5 | | (24) violating State or federal laws or regulations
|
6 | | relating to controlled substances or other legend drugs or |
7 | | ephedra as defined in the Ephedra Prohibition Act; |
8 | | (25) failure to establish and maintain records of
|
9 | | patient care and treatment as required by law; |
10 | | (26) attempting to subvert or cheat on the
required |
11 | | examinations; |
12 | | (27) willfully failing to report an instance of
|
13 | | suspected abuse, neglect, financial exploitation, or |
14 | | self-neglect of an eligible adult as defined in and |
15 | | required by the Adult Protective Services Act; |
16 | | (28) being named as an abuser in a verified report by
|
17 | | the Department on Aging under the Adult Protective |
18 | | Services Act and upon proof by clear and convincing |
19 | | evidence that the licensee abused, neglected, or |
20 | | financially exploited an eligible adult as defined in the |
21 | | Adult Protective Services Act; |
22 | | (29) failure to report to the Department an adverse
|
23 | | final action taken against the individual by another |
24 | | licensing jurisdiction of the United States or a foreign |
25 | | state or country, a peer review body, a health care |
26 | | institution, a professional society or association, a |
|
| | HB3721 | - 25 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | governmental agency, a law enforcement agency, or a court |
2 | | acts or conduct similar to acts or conduct that would |
3 | | constitute grounds for action under this Section; and |
4 | | (30) failure to provide copies of records of patient
|
5 | | care or treatment, except as required by law. |
6 | | (b) The Department may refuse to issue or may suspend |
7 | | without hearing, as provided for in the Code of Civil |
8 | | Procedure, the license of any person who fails to file a |
9 | | return, or pay the tax, penalty, or interest shown in a filed |
10 | | return, or pay any final assessment of the tax, penalty, or |
11 | | interest as required by any tax Act administered by the |
12 | | Illinois Department of Revenue, until the requirements of any |
13 | | such tax Act are satisfied in accordance with subsection (g) |
14 | | of Section 2105-15 of the Civil Administrative Code of |
15 | | Illinois. |
16 | | (c) The determination by a circuit court that a licensee |
17 | | is subject to involuntary admission or judicial admission as |
18 | | provided in the Mental Health and Developmental Disabilities |
19 | | Code operates as an automatic suspension. The suspension will |
20 | | end only upon a finding by a court that the patient is no |
21 | | longer subject to involuntary admission or judicial admission |
22 | | and issues an order so finding and discharging the patient, |
23 | | and upon the recommendation of the Board to the Department |
24 | | that the licensee be allowed to resume the licensee's |
25 | | practice. |
26 | | (d) In enforcing this Section, the Department upon a |
|
| | HB3721 | - 26 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | showing of a possible violation may compel an individual |
2 | | licensed to practice under this Act, or who has applied for |
3 | | licensure under this Act, to submit to a mental or physical |
4 | | examination, or both, which may include a substance abuse or |
5 | | sexual offender evaluation, as required by and at the expense |
6 | | of the Department. |
7 | | The Department shall specifically designate the examining |
8 | | physician licensed to practice medicine in all of its branches |
9 | | or, if applicable, the multidisciplinary team involved in |
10 | | providing the mental or physical examination or both. The |
11 | | multidisciplinary team shall be led by a physician licensed to |
12 | | practice medicine in all of its branches and may consist of one |
13 | | or more or a combination of physicians licensed to practice |
14 | | medicine in all of its branches, licensed clinical |
15 | | psychologists, licensed clinical social workers, licensed |
16 | | clinical professional counselors, and other professional and |
17 | | administrative staff. Any examining physician or member of the |
18 | | multidisciplinary team may require any person ordered to |
19 | | submit to an examination pursuant to this Section to submit to |
20 | | any additional supplemental testing deemed necessary to |
21 | | complete any examination or evaluation process, including, but |
22 | | not limited to, blood testing, urinalysis, psychological |
23 | | testing, or neuropsychological testing. |
24 | | The Department may order the examining physician or any |
25 | | member of the multidisciplinary team to provide to the |
26 | | Department any and all records, including business records, |
|
| | HB3721 | - 27 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | that relate to the examination and evaluation, including any |
2 | | supplemental testing performed. |
3 | | The Department may order the examining physician or any |
4 | | member of the multidisciplinary team to present testimony |
5 | | concerning the mental or physical examination of the licensee |
6 | | or applicant. No information, report, record, or other |
7 | | documents in any way related to the examination shall be |
8 | | excluded by reason of any common law or statutory privilege |
9 | | relating to communications between the licensee or applicant |
10 | | and the examining physician or any member of the |
11 | | multidisciplinary team. No authorization is necessary from the |
12 | | licensee or applicant ordered to undergo an examination for |
13 | | the examining physician or any member of the multidisciplinary |
14 | | team to provide information, reports, records, or other |
15 | | documents or to provide any testimony regarding the |
16 | | examination and evaluation. |
17 | | The individual to be examined may have, at the |
18 | | individual's own expense, another physician of the |
19 | | individual's choice present during all aspects of this |
20 | | examination. However, that physician shall be present only to |
21 | | observe and may not interfere in any way with the examination. |
22 | | Failure of an individual to submit to a mental or physical |
23 | | examination, when ordered, shall result in an automatic |
24 | | suspension of the individual's license until the individual |
25 | | submits to the examination. |
26 | | If the Department finds an individual unable to practice |
|
| | HB3721 | - 28 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | because of the reasons set forth in this Section, the |
2 | | Department may require that individual to submit to care, |
3 | | counseling, or treatment by physicians approved or designated |
4 | | by the Department, as a condition, term, or restriction for |
5 | | continued, reinstated, or renewed licensure to practice; or, |
6 | | in lieu of care, counseling, or treatment, the Department may |
7 | | file a complaint to immediately suspend, revoke, or otherwise |
8 | | discipline the license of the individual. An individual whose |
9 | | license was granted, continued, reinstated, renewed, |
10 | | disciplined, or supervised subject to such terms, conditions, |
11 | | or restrictions, and who fails to comply with such terms, |
12 | | conditions, or restrictions, shall be referred to the |
13 | | Secretary for a determination as to whether the individual |
14 | | shall have his or her license suspended immediately, pending a |
15 | | hearing by the Department. |
16 | | In instances in which the Department immediately suspends |
17 | | a person's license under this Section, a hearing on that |
18 | | person's license must be convened by the Department within 30 |
19 | | days after the suspension and completed without appreciable |
20 | | delay. The Department shall have the authority to review the |
21 | | subject individual's record of treatment and counseling |
22 | | regarding the impairment to the extent permitted by applicable |
23 | | federal statutes and regulations safeguarding the |
24 | | confidentiality of medical records. |
25 | | An individual licensed under this Act and affected under |
26 | | this Section shall be afforded an opportunity to demonstrate |
|
| | HB3721 | - 29 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | to the Department that the individual can resume practice in |
2 | | compliance with acceptable and prevailing standards under the |
3 | | provisions of the individual's license. |
4 | | (e) An individual or organization acting in good faith, |
5 | | and not in a willful and wanton manner, in complying with this |
6 | | Section by providing a report or other information to the |
7 | | Department, by assisting in the investigation or preparation |
8 | | of a report or information, by participating in proceedings of |
9 | | the Department, or by serving as a member of the Department, |
10 | | shall not be subject to criminal prosecution or civil damages |
11 | | as a result of such actions. |
12 | | (f) Members of the Board and the Department shall be |
13 | | indemnified by the State for any actions occurring within the |
14 | | scope of services under the Act, done in good faith and not |
15 | | willful and wanton in nature. The Attorney General shall |
16 | | defend all such actions unless the Attorney General determines |
17 | | either that there would be a conflict of interest in such |
18 | | representation or that the actions complained of were not in |
19 | | good faith or were willful and wanton. |
20 | | If the Attorney General declines representation, the |
21 | | member has the right to employ counsel of the member's choice, |
22 | | whose fees shall be provided by the State, after approval by |
23 | | the Attorney General, unless there is a determination by a |
24 | | court that the member's actions were not in good faith or were |
25 | | willful and wanton. |
26 | | The member must notify the Attorney General within 7 days |
|
| | HB3721 | - 30 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | after receipt of notice of the initiation of any action |
2 | | involving services of the Board. Failure to so notify the |
3 | | Attorney General constitutes an absolute waiver of the right |
4 | | to a defense and indemnification. |
5 | | The Attorney General shall determine, within 7 days after |
6 | | receiving such notice, whether the Attorney General will |
7 | | undertake to represent the member. |
8 | | Section 75. Investigation; notice; hearing. The Department |
9 | | may investigate the actions of any applicant or of any person |
10 | | or persons holding or claiming to hold a license. The |
11 | | Department shall, before suspending, revoking, placing on |
12 | | probationary status, or taking any other disciplinary action |
13 | | as the Department may deem proper with regard to any license, |
14 | | at least 30 days prior to the date set for the hearing, notify |
15 | | the licensee in writing of any charges made and the time and |
16 | | place for a hearing of the charges before the Department, |
17 | | direct the licensee to file the licensee's written answer |
18 | | thereto to the Department under oath within 20 days after the |
19 | | service on the licensee of such notice and inform the licensee |
20 | | that if the licensee fails to file such answer, default will be |
21 | | taken against the licensee and the license may be suspended, |
22 | | revoked, placed on probationary status, or have other |
23 | | disciplinary action, including limiting the scope, nature or |
24 | | extent of the licensee's practice, as the Department may deem |
25 | | proper taken with regard thereto. Written or electronic notice |
|
| | HB3721 | - 31 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | may be served by personal delivery, email, or mail to the |
2 | | applicant or licensee at the licensee's address of record or |
3 | | email address of record. At the time and place fixed in the |
4 | | notice, the Department shall proceed to hear the charges and |
5 | | the parties or their counsel shall be accorded ample |
6 | | opportunity to present such statements, testimony, evidence, |
7 | | and argument as may be pertinent to the charges or to the |
8 | | defense thereto. The Department may continue such hearing from |
9 | | time to time. In case the applicant or licensee, after |
10 | | receiving notice, fails to file an answer, the licensee's |
11 | | license may in the discretion of the Secretary, having |
12 | | received first the recommendation of the Department, be |
13 | | suspended, revoked, placed on probationary status, or the |
14 | | Department may take whatever disciplinary action as the |
15 | | Department may deem proper, including limiting the scope, |
16 | | nature, or extent of such person's practice, without a |
17 | | hearing, if the act or acts charged constitute sufficient |
18 | | grounds for such action under this Act. |
19 | | Section 80. Record of proceedings. The Department, at its |
20 | | expense, shall preserve a record of all proceedings at the |
21 | | formal hearing of any case involving the refusal to issue or |
22 | | renew a license or discipline a licensee. The notice of |
23 | | hearing, complaint, and all other documents in the nature of |
24 | | pleadings and written motions filed in the proceedings, the |
25 | | transcript of testimony, the report of the Department, and |
|
| | HB3721 | - 32 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | orders of the Department shall be the record of such |
2 | | proceeding. |
3 | | Section 85. Confidentiality. All information collected by |
4 | | the Department in the course of an examination or |
5 | | investigation of a licensee or applicant, including, but not |
6 | | limited to, any complaint against a licensee filed with the |
7 | | Department and information collected to investigate any such |
8 | | complaint, shall be maintained for the confidential use of the |
9 | | Department and shall not be disclosed. The Department shall |
10 | | not disclose the information to anyone other than law |
11 | | enforcement officials, regulatory agencies that have an |
12 | | appropriate regulatory interest as determined by the |
13 | | Department, or a party presenting a lawful subpoena to the |
14 | | Department. Information and documents disclosed to a federal, |
15 | | State, county, or local law enforcement agency shall not be |
16 | | disclosed by the agency for any purpose to any other agency or |
17 | | person. A formal complaint filed against a licensee by the |
18 | | Department or any order issued by the Department against a |
19 | | licensee or applicant shall be a public record, except as |
20 | | otherwise prohibited by law. |
21 | | Section 90. Illinois Administrative Procedure Act. The |
22 | | Illinois Administrative Procedure Act is expressly adopted and |
23 | | incorporated herein as if all of the provisions of that Act |
24 | | were included in this Act, except that the provision of |
|
| | HB3721 | - 33 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | paragraph (d) of Section 10-65 of the Illinois Administrative |
2 | | Procedure Act, which provides that at hearings the licensee or |
3 | | person holding a license has the right to show compliance with |
4 | | all lawful requirements for retention or continuation of the |
5 | | license, is specifically excluded. For the purpose of this |
6 | | Act, the notice required under Section 10-25 of the Illinois |
7 | | Administrative Procedure Act is deemed sufficient when |
8 | | personally served, mailed to the address of record of the |
9 | | applicant or licensee, or emailed to the email address of |
10 | | record of the applicant or licensee. |
11 | | Section 100. The Illinois Controlled Substances Act is |
12 | | amended by changing Section 102 as follows: |
13 | | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) |
14 | | Sec. 102. Definitions. As used in this Act, unless the |
15 | | context
otherwise requires:
|
16 | | (a) "Addict" means any person who habitually uses any |
17 | | drug, chemical,
substance or dangerous drug other than alcohol |
18 | | so as to endanger the public
morals, health, safety or welfare |
19 | | or who is so far addicted to the use of a
dangerous drug or |
20 | | controlled substance other than alcohol as to have lost
the |
21 | | power of self control with reference to his or her addiction.
|
22 | | (b) "Administer" means the direct application of a |
23 | | controlled
substance, whether by injection, inhalation, |
24 | | ingestion, or any other
means, to the body of a patient, |
|
| | HB3721 | - 34 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | research subject, or animal (as
defined by the Humane |
2 | | Euthanasia in Animal Shelters Act) by:
|
3 | | (1) a practitioner (or, in his or her presence, by his |
4 | | or her authorized agent),
|
5 | | (2) the patient or research subject pursuant to an |
6 | | order, or
|
7 | | (3) a euthanasia technician as defined by the Humane |
8 | | Euthanasia in
Animal Shelters Act.
|
9 | | (c) "Agent" means an authorized person who acts on behalf |
10 | | of or at
the direction of a manufacturer, distributor, |
11 | | dispenser, prescriber, or practitioner. It does not
include a |
12 | | common or contract carrier, public warehouseman or employee of
|
13 | | the carrier or warehouseman.
|
14 | | (c-1) "Anabolic Steroids" means any drug or hormonal |
15 | | substance,
chemically and pharmacologically related to |
16 | | testosterone (other than
estrogens, progestins, |
17 | | corticosteroids, and dehydroepiandrosterone),
and includes:
|
18 | | (i) 3[beta],17-dihydroxy-5a-androstane, |
19 | | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, |
20 | | (iii) 5[alpha]-androstan-3,17-dione, |
21 | | (iv) 1-androstenediol (3[beta], |
22 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), |
23 | | (v) 1-androstenediol (3[alpha], |
24 | | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), |
25 | | (vi) 4-androstenediol |
26 | | (3[beta],17[beta]-dihydroxy-androst-4-ene), |
|
| | HB3721 | - 35 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (vii) 5-androstenediol |
2 | | (3[beta],17[beta]-dihydroxy-androst-5-ene), |
3 | | (viii) 1-androstenedione |
4 | | ([5alpha]-androst-1-en-3,17-dione), |
5 | | (ix) 4-androstenedione |
6 | | (androst-4-en-3,17-dione), |
7 | | (x) 5-androstenedione |
8 | | (androst-5-en-3,17-dione), |
9 | | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- |
10 | | hydroxyandrost-4-en-3-one), |
11 | | (xii) boldenone (17[beta]-hydroxyandrost- |
12 | | 1,4,-diene-3-one), |
13 | | (xiii) boldione (androsta-1,4- |
14 | | diene-3,17-dione), |
15 | | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 |
16 | | [beta]-hydroxyandrost-4-en-3-one), |
17 | | (xv) clostebol (4-chloro-17[beta]- |
18 | | hydroxyandrost-4-en-3-one), |
19 | | (xvi) dehydrochloromethyltestosterone (4-chloro- |
20 | | 17[beta]-hydroxy-17[alpha]-methyl- |
21 | | androst-1,4-dien-3-one), |
22 | | (xvii) desoxymethyltestosterone |
23 | | (17[alpha]-methyl-5[alpha] |
24 | | -androst-2-en-17[beta]-ol)(a.k.a., madol), |
25 | | (xviii) [delta]1-dihydrotestosterone (a.k.a. |
26 | | '1-testosterone') (17[beta]-hydroxy- |
|
| | HB3721 | - 36 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | 5[alpha]-androst-1-en-3-one), |
2 | | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- |
3 | | androstan-3-one), |
4 | | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- |
5 | | 5[alpha]-androstan-3-one), |
6 | | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- |
7 | | hydroxyestr-4-ene), |
8 | | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- |
9 | | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), |
10 | | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], |
11 | | 17[beta]-dihydroxyandrost-1,4-dien-3-one), |
12 | | (xxiv) furazabol (17[alpha]-methyl-17[beta]- |
13 | | hydroxyandrostano[2,3-c]-furazan), |
14 | | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, |
15 | | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- |
16 | | androst-4-en-3-one), |
17 | | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- |
18 | | dihydroxy-estr-4-en-3-one), |
19 | | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- |
20 | | hydroxy-5-androstan-3-one), |
21 | | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- |
22 | | [5a]-androstan-3-one), |
23 | | (xxx) methandienone (17[alpha]-methyl-17[beta]- |
24 | | hydroxyandrost-1,4-dien-3-one), |
25 | | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- |
26 | | dihydroxyandrost-5-ene), |
|
| | HB3721 | - 37 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- |
2 | | 5[alpha]-androst-1-en-3-one), |
3 | | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- |
4 | | dihydroxy-5a-androstane, |
5 | | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy |
6 | | -5a-androstane, |
7 | | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- |
8 | | dihydroxyandrost-4-ene), |
9 | | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- |
10 | | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), |
11 | | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- |
12 | | hydroxyestra-4,9(10)-dien-3-one), |
13 | | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- |
14 | | hydroxyestra-4,9-11-trien-3-one), |
15 | | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- |
16 | | hydroxyandrost-4-en-3-one), |
17 | | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- |
18 | | hydroxyestr-4-en-3-one), |
19 | | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone |
20 | | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- |
21 | | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- |
22 | | 1-testosterone'), |
23 | | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), |
24 | | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- |
25 | | dihydroxyestr-4-ene), |
26 | | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- |
|
| | HB3721 | - 38 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | dihydroxyestr-4-ene), |
2 | | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- |
3 | | dihydroxyestr-5-ene), |
4 | | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- |
5 | | dihydroxyestr-5-ene), |
6 | | (xlvii) 19-nor-4,9(10)-androstadienedione |
7 | | (estra-4,9(10)-diene-3,17-dione), |
8 | | (xlviii) 19-nor-4-androstenedione (estr-4- |
9 | | en-3,17-dione), |
10 | | (xlix) 19-nor-5-androstenedione (estr-5- |
11 | | en-3,17-dione), |
12 | | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- |
13 | | hydroxygon-4-en-3-one), |
14 | | (li) norclostebol (4-chloro-17[beta]- |
15 | | hydroxyestr-4-en-3-one), |
16 | | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- |
17 | | hydroxyestr-4-en-3-one), |
18 | | (liii) normethandrolone (17[alpha]-methyl-17[beta]- |
19 | | hydroxyestr-4-en-3-one), |
20 | | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- |
21 | | 2-oxa-5[alpha]-androstan-3-one), |
22 | | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- |
23 | | dihydroxyandrost-4-en-3-one), |
24 | | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- |
25 | | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), |
26 | | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- |
|
| | HB3721 | - 39 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), |
2 | | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- |
3 | | (5[alpha]-androst-1-en-3-one), |
4 | | (lix) testolactone (13-hydroxy-3-oxo-13,17- |
5 | | secoandrosta-1,4-dien-17-oic |
6 | | acid lactone), |
7 | | (lx) testosterone (17[beta]-hydroxyandrost- |
8 | | 4-en-3-one), |
9 | | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- |
10 | | diethyl-17[beta]-hydroxygon- |
11 | | 4,9,11-trien-3-one), |
12 | | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, |
13 | | 11-trien-3-one).
|
14 | | Any person who is otherwise lawfully in possession of an |
15 | | anabolic
steroid, or who otherwise lawfully manufactures, |
16 | | distributes, dispenses,
delivers, or possesses with intent to |
17 | | deliver an anabolic steroid, which
anabolic steroid is |
18 | | expressly intended for and lawfully allowed to be
administered |
19 | | through implants to livestock or other nonhuman species, and
|
20 | | which is approved by the Secretary of Health and Human |
21 | | Services for such
administration, and which the person intends |
22 | | to administer or have
administered through such implants, |
23 | | shall not be considered to be in
unauthorized possession or to |
24 | | unlawfully manufacture, distribute, dispense,
deliver, or |
25 | | possess with intent to deliver such anabolic steroid for
|
26 | | purposes of this Act.
|
|
| | HB3721 | - 40 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (d) "Administration" means the Drug Enforcement |
2 | | Administration,
United States Department of Justice, or its |
3 | | successor agency.
|
4 | | (d-5) "Clinical Director, Prescription Monitoring Program" |
5 | | means a Department of Human Services administrative employee |
6 | | licensed to either prescribe or dispense controlled substances |
7 | | who shall run the clinical aspects of the Department of Human |
8 | | Services Prescription Monitoring Program and its Prescription |
9 | | Information Library. |
10 | | (d-10) "Compounding" means the preparation and mixing of |
11 | | components, excluding flavorings, (1) as the result of a |
12 | | prescriber's prescription drug order or initiative based on |
13 | | the prescriber-patient-pharmacist relationship in the course |
14 | | of professional practice or (2) for the purpose of, or |
15 | | incident to, research, teaching, or chemical analysis and not |
16 | | for sale or dispensing. "Compounding" includes the preparation |
17 | | of drugs or devices in anticipation of receiving prescription |
18 | | drug orders based on routine, regularly observed dispensing |
19 | | patterns. Commercially available products may be compounded |
20 | | for dispensing to individual patients only if both of the |
21 | | following conditions are met: (i) the commercial product is |
22 | | not reasonably available from normal distribution channels in |
23 | | a timely manner to meet the patient's needs and (ii) the |
24 | | prescribing practitioner has requested that the drug be |
25 | | compounded. |
26 | | (e) "Control" means to add a drug or other substance, or |
|
| | HB3721 | - 41 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | immediate
precursor, to a Schedule whether by
transfer from |
2 | | another Schedule or otherwise.
|
3 | | (f) "Controlled Substance" means (i) a drug, substance, |
4 | | immediate
precursor, or synthetic drug in the Schedules of |
5 | | Article II of this Act or (ii) a drug or other substance, or |
6 | | immediate precursor, designated as a controlled substance by |
7 | | the Department through administrative rule. The term does not |
8 | | include distilled spirits, wine, malt beverages, or tobacco, |
9 | | as those terms are
defined or used in the Liquor Control Act of |
10 | | 1934 and the Tobacco Products Tax
Act of 1995.
|
11 | | (f-5) "Controlled substance analog" means a substance: |
12 | | (1) the chemical structure of which is substantially |
13 | | similar to the chemical structure of a controlled |
14 | | substance in Schedule I or II; |
15 | | (2) which has a stimulant, depressant, or |
16 | | hallucinogenic effect on the central nervous system that |
17 | | is substantially similar to or greater than the stimulant, |
18 | | depressant, or hallucinogenic effect on the central |
19 | | nervous system of a controlled substance in Schedule I or |
20 | | II; or |
21 | | (3) with respect to a particular person, which such |
22 | | person represents or intends to have a stimulant, |
23 | | depressant, or hallucinogenic effect on the central |
24 | | nervous system that is substantially similar to or greater |
25 | | than the stimulant, depressant, or hallucinogenic effect |
26 | | on the central nervous system of a controlled substance in |
|
| | HB3721 | - 42 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | Schedule I or II. |
2 | | (g) "Counterfeit substance" means a controlled substance, |
3 | | which, or
the container or labeling of which, without |
4 | | authorization bears the
trademark, trade name, or other |
5 | | identifying mark, imprint, number or
device, or any likeness |
6 | | thereof, of a manufacturer, distributor, or
dispenser other |
7 | | than the person who in fact manufactured, distributed,
or |
8 | | dispensed the substance.
|
9 | | (h) "Deliver" or "delivery" means the actual, constructive |
10 | | or
attempted transfer of possession of a controlled substance, |
11 | | with or
without consideration, whether or not there is an |
12 | | agency relationship.
"Deliver" or "delivery" does not include
|
13 | | the donation of drugs to the extent permitted
under the |
14 | | Illinois Drug Reuse Opportunity Program Act.
|
15 | | (i) "Department" means the Illinois Department of Human |
16 | | Services (as
successor to the Department of Alcoholism and |
17 | | Substance Abuse) or its successor agency.
|
18 | | (j) (Blank).
|
19 | | (k) "Department of Corrections" means the Department of |
20 | | Corrections
of the State of Illinois or its successor agency.
|
21 | | (l) "Department of Financial and Professional Regulation" |
22 | | means the Department
of Financial and Professional Regulation |
23 | | of the State of Illinois or its successor agency.
|
24 | | (m) "Depressant" means any drug that (i) causes an overall |
25 | | depression of central nervous system functions, (ii) causes |
26 | | impaired consciousness and awareness, and (iii) can be |
|
| | HB3721 | - 43 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | habit-forming or lead to a substance abuse problem, including, |
2 | | but not limited to, alcohol, cannabis and its active |
3 | | principles and their analogs, benzodiazepines and their |
4 | | analogs, barbiturates and their analogs, opioids (natural and |
5 | | synthetic) and their analogs, and chloral hydrate and similar |
6 | | sedative hypnotics.
|
7 | | (n) (Blank).
|
8 | | (o) "Director" means the Director of the Illinois State |
9 | | Police or his or her designated agents.
|
10 | | (p) "Dispense" means to deliver a controlled substance to |
11 | | an
ultimate user or research subject by or pursuant to the |
12 | | lawful order of
a prescriber, including the prescribing, |
13 | | administering, packaging,
labeling, or compounding necessary |
14 | | to prepare the substance for that
delivery.
|
15 | | (q) "Dispenser" means a practitioner who dispenses.
|
16 | | (r) "Distribute" means to deliver, other than by |
17 | | administering or
dispensing, a controlled substance.
|
18 | | (s) "Distributor" means a person who distributes.
|
19 | | (t) "Drug" means (1) substances recognized as drugs in the |
20 | | official
United States Pharmacopoeia, Official Homeopathic |
21 | | Pharmacopoeia of the
United States, or official National |
22 | | Formulary, or any supplement to any
of them; (2) substances |
23 | | intended for use in diagnosis, cure, mitigation,
treatment, or |
24 | | prevention of disease in man or animals; (3) substances
(other |
25 | | than food) intended to affect the structure of any function of
|
26 | | the body of man or animals and (4) substances intended for use |
|
| | HB3721 | - 44 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | as a
component of any article specified in clause (1), (2), or |
2 | | (3) of this
subsection. It does not include devices or their |
3 | | components, parts, or
accessories.
|
4 | | (t-3) "Electronic health record" or "EHR" means an |
5 | | electronic record of health-related information on an |
6 | | individual that is created, gathered, managed, and consulted |
7 | | by authorized health care clinicians and staff. |
8 | | (t-3.5) "Electronic health record system" or "EHR system" |
9 | | means any computer-based system or combination of federally |
10 | | certified Health IT Modules (defined at 42 CFR 170.102 or its |
11 | | successor) used as a repository for electronic health records |
12 | | and accessed or updated by a prescriber or authorized |
13 | | surrogate in the ordinary course of his or her medical |
14 | | practice. For purposes of connecting to the Prescription |
15 | | Information Library maintained by the Bureau of Pharmacy and |
16 | | Clinical Support Systems or its successor, an EHR system may |
17 | | connect to the Prescription Information Library directly or |
18 | | through all or part of a computer program or system that is a |
19 | | federally certified Health IT Module maintained by a third |
20 | | party and used by the EHR system to secure access to the |
21 | | database. |
22 | | (t-4) "Emergency medical services personnel" has the |
23 | | meaning ascribed to it in the Emergency Medical Services (EMS) |
24 | | Systems Act. |
25 | | (t-5) "Euthanasia agency" means
an entity certified by the |
26 | | Department of Financial and Professional Regulation for the
|
|
| | HB3721 | - 45 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | purpose of animal euthanasia that holds an animal control |
2 | | facility license or
animal
shelter license under the Animal |
3 | | Welfare Act. A euthanasia agency is
authorized to purchase, |
4 | | store, possess, and utilize Schedule II nonnarcotic and
|
5 | | Schedule III nonnarcotic drugs for the sole purpose of animal |
6 | | euthanasia.
|
7 | | (t-10) "Euthanasia drugs" means Schedule II or Schedule |
8 | | III substances
(nonnarcotic controlled substances) that are |
9 | | used by a euthanasia agency for
the purpose of animal |
10 | | euthanasia.
|
11 | | (u) "Good faith" means the prescribing or dispensing of a |
12 | | controlled
substance by a practitioner in the regular course |
13 | | of professional
treatment to or for any person who is under his |
14 | | or her treatment for a
pathology or condition other than that |
15 | | individual's physical or
psychological dependence upon or |
16 | | addiction to a controlled substance,
except as provided |
17 | | herein: and application of the term to a pharmacist
shall mean |
18 | | the dispensing of a controlled substance pursuant to the
|
19 | | prescriber's order which in the professional judgment of the |
20 | | pharmacist
is lawful. The pharmacist shall be guided by |
21 | | accepted professional
standards, including, but not limited |
22 | | to, the following, in making the
judgment:
|
23 | | (1) lack of consistency of prescriber-patient |
24 | | relationship,
|
25 | | (2) frequency of prescriptions for same drug by one |
26 | | prescriber for
large numbers of patients,
|
|
| | HB3721 | - 46 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (3) quantities beyond those normally prescribed,
|
2 | | (4) unusual dosages (recognizing that there may be |
3 | | clinical circumstances where more or less than the usual |
4 | | dose may be used legitimately),
|
5 | | (5) unusual geographic distances between patient, |
6 | | pharmacist and
prescriber,
|
7 | | (6) consistent prescribing of habit-forming drugs.
|
8 | | (u-0.5) "Hallucinogen" means a drug that causes markedly |
9 | | altered sensory perception leading to hallucinations of any |
10 | | type. |
11 | | (u-1) "Home infusion services" means services provided by |
12 | | a pharmacy in
compounding solutions for direct administration |
13 | | to a patient in a private
residence, long-term care facility, |
14 | | or hospice setting by means of parenteral,
intravenous, |
15 | | intramuscular, subcutaneous, or intraspinal infusion.
|
16 | | (u-5) "Illinois State Police" means the Illinois State
|
17 | | Police or its successor agency. |
18 | | (v) "Immediate precursor" means a substance:
|
19 | | (1) which the Department has found to be and by rule |
20 | | designated as
being a principal compound used, or produced |
21 | | primarily for use, in the
manufacture of a controlled |
22 | | substance;
|
23 | | (2) which is an immediate chemical intermediary used |
24 | | or likely to
be used in the manufacture of such controlled |
25 | | substance; and
|
26 | | (3) the control of which is necessary to prevent, |
|
| | HB3721 | - 47 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | curtail or limit
the manufacture of such controlled |
2 | | substance.
|
3 | | (w) "Instructional activities" means the acts of teaching, |
4 | | educating
or instructing by practitioners using controlled |
5 | | substances within
educational facilities approved by the State |
6 | | Board of Education or
its successor agency.
|
7 | | (x) "Local authorities" means a duly organized State, |
8 | | County or
Municipal peace unit or police force.
|
9 | | (y) "Look-alike substance" means a substance, other than a |
10 | | controlled
substance which (1) by overall dosage unit |
11 | | appearance, including shape,
color, size, markings or lack |
12 | | thereof, taste, consistency, or any other
identifying physical |
13 | | characteristic of the substance, would lead a reasonable
|
14 | | person to believe that the substance is a controlled |
15 | | substance, or (2) is
expressly or impliedly represented to be |
16 | | a controlled substance or is
distributed under circumstances |
17 | | which would lead a reasonable person to
believe that the |
18 | | substance is a controlled substance. For the purpose of
|
19 | | determining whether the representations made or the |
20 | | circumstances of the
distribution would lead a reasonable |
21 | | person to believe the substance to be
a controlled substance |
22 | | under this clause (2) of subsection (y), the court or
other |
23 | | authority may consider the following factors in addition to |
24 | | any other
factor that may be relevant:
|
25 | | (a) statements made by the owner or person in control |
26 | | of the substance
concerning its nature, use or effect;
|
|
| | HB3721 | - 48 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (b) statements made to the buyer or recipient that the |
2 | | substance may
be resold for profit;
|
3 | | (c) whether the substance is packaged in a manner |
4 | | normally used for the
illegal distribution of controlled |
5 | | substances;
|
6 | | (d) whether the distribution or attempted distribution |
7 | | included an
exchange of or demand for money or other |
8 | | property as consideration, and
whether the amount of the |
9 | | consideration was substantially greater than the
|
10 | | reasonable retail market value of the substance.
|
11 | | Clause (1) of this subsection (y) shall not apply to a |
12 | | noncontrolled
substance in its finished dosage form that was |
13 | | initially introduced into
commerce prior to the initial |
14 | | introduction into commerce of a controlled
substance in its |
15 | | finished dosage form which it may substantially resemble.
|
16 | | Nothing in this subsection (y) prohibits the dispensing or |
17 | | distributing
of noncontrolled substances by persons authorized |
18 | | to dispense and
distribute controlled substances under this |
19 | | Act, provided that such action
would be deemed to be carried |
20 | | out in good faith under subsection (u) if the
substances |
21 | | involved were controlled substances.
|
22 | | Nothing in this subsection (y) or in this Act prohibits |
23 | | the manufacture,
preparation, propagation, compounding, |
24 | | processing, packaging, advertising
or distribution of a drug |
25 | | or drugs by any person registered pursuant to
Section 510 of |
26 | | the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
|
|
| | HB3721 | - 49 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (y-1) "Mail-order pharmacy" means a pharmacy that is |
2 | | located in a state
of the United States that delivers, |
3 | | dispenses or
distributes, through the United States Postal |
4 | | Service or other common
carrier, to Illinois residents, any |
5 | | substance which requires a prescription.
|
6 | | (z) "Manufacture" means the production, preparation, |
7 | | propagation,
compounding, conversion or processing of a |
8 | | controlled substance other than methamphetamine, either
|
9 | | directly or indirectly, by extraction from substances of |
10 | | natural origin,
or independently by means of chemical |
11 | | synthesis, or by a combination of
extraction and chemical |
12 | | synthesis, and includes any packaging or
repackaging of the |
13 | | substance or labeling of its container, except that
this term |
14 | | does not include:
|
15 | | (1) by an ultimate user, the preparation or |
16 | | compounding of a
controlled substance for his or her own |
17 | | use;
|
18 | | (2) by a practitioner, or his or her authorized agent |
19 | | under his or her
supervision, the preparation, |
20 | | compounding, packaging, or labeling of a
controlled |
21 | | substance:
|
22 | | (a) as an incident to his or her administering or |
23 | | dispensing of a
controlled substance in the course of |
24 | | his or her professional practice; or
|
25 | | (b) as an incident to lawful research, teaching or |
26 | | chemical
analysis and not for sale; or
|
|
| | HB3721 | - 50 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | (3) the packaging, repackaging, or labeling of
drugs |
2 | | only to the extent permitted under the
Illinois Drug Reuse |
3 | | Opportunity Program Act.
|
4 | | (z-1) (Blank).
|
5 | | (z-5) "Medication shopping" means the conduct prohibited |
6 | | under subsection (a) of Section 314.5 of this Act. |
7 | | (z-10) "Mid-level practitioner" means (i) a physician |
8 | | assistant who has been delegated authority to prescribe |
9 | | through a written delegation of authority by a physician |
10 | | licensed to practice medicine in all of its branches, in |
11 | | accordance with Section 7.5 of the Physician Assistant |
12 | | Practice Act of 1987, (ii) an advanced practice registered |
13 | | nurse who has been delegated authority to prescribe through a |
14 | | written delegation of authority by a physician licensed to |
15 | | practice medicine in all of its branches or by a podiatric |
16 | | physician, in accordance with Section 65-40 of the Nurse |
17 | | Practice Act, (iii) an advanced practice registered nurse |
18 | | certified as a nurse practitioner, nurse midwife, or clinical |
19 | | nurse specialist who has been granted authority to prescribe |
20 | | by a hospital affiliate in accordance with Section 65-45 of |
21 | | the Nurse Practice Act, (iv) an animal euthanasia agency, or |
22 | | (v) a prescribing psychologist. |
23 | | (aa) "Narcotic drug" means any of the following, whether |
24 | | produced
directly or indirectly by extraction from substances |
25 | | of vegetable origin,
or independently by means of chemical |
26 | | synthesis, or by a combination of
extraction and chemical |
|
| | HB3721 | - 51 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | synthesis:
|
2 | | (1) opium, opiates, derivatives of opium and opiates, |
3 | | including their isomers, esters, ethers, salts, and salts |
4 | | of isomers, esters, and ethers, whenever the existence of |
5 | | such isomers, esters, ethers, and salts is possible within |
6 | | the specific chemical designation; however the term |
7 | | "narcotic drug" does not include the isoquinoline |
8 | | alkaloids of opium;
|
9 | | (2) (blank);
|
10 | | (3) opium poppy and poppy straw;
|
11 | | (4) coca leaves, except coca leaves and extracts of |
12 | | coca leaves from which substantially all of the cocaine |
13 | | and ecgonine, and their isomers, derivatives and salts, |
14 | | have been removed;
|
15 | | (5) cocaine, its salts, optical and geometric isomers, |
16 | | and salts of isomers; |
17 | | (6) ecgonine, its derivatives, their salts, isomers, |
18 | | and salts of isomers; |
19 | | (7) any compound, mixture, or preparation which |
20 | | contains any quantity of any of the substances referred to |
21 | | in subparagraphs (1) through (6). |
22 | | (bb) "Nurse" means a registered nurse licensed under the
|
23 | | Nurse Practice Act.
|
24 | | (cc) (Blank).
|
25 | | (dd) "Opiate" means any substance having an addiction |
26 | | forming or
addiction sustaining liability similar to morphine |
|
| | HB3721 | - 52 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | or being capable of
conversion into a drug having addiction |
2 | | forming or addiction sustaining
liability.
|
3 | | (ee) "Opium poppy" means the plant of the species Papaver
|
4 | | somniferum L., except its seeds.
|
5 | | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or |
6 | | solution or other liquid form of medication intended for |
7 | | administration by mouth, but the term does not include a form |
8 | | of medication intended for buccal, sublingual, or transmucosal |
9 | | administration. |
10 | | (ff) "Parole and Pardon Board" means the Parole and Pardon |
11 | | Board of
the State of Illinois or its successor agency.
|
12 | | (gg) "Person" means any individual, corporation, |
13 | | mail-order pharmacy,
government or governmental subdivision or |
14 | | agency, business trust, estate,
trust, partnership or |
15 | | association, or any other entity.
|
16 | | (hh) "Pharmacist" means any person who holds a license or |
17 | | certificate of
registration as a registered pharmacist, a |
18 | | local registered pharmacist
or a registered assistant |
19 | | pharmacist under the Pharmacy Practice Act.
|
20 | | (ii) "Pharmacy" means any store, ship or other place in |
21 | | which
pharmacy is authorized to be practiced under the |
22 | | Pharmacy Practice Act.
|
23 | | (ii-5) "Pharmacy shopping" means the conduct prohibited |
24 | | under subsection (b) of Section 314.5 of this Act. |
25 | | (ii-10) "Physician" (except when the context otherwise |
26 | | requires) means a person licensed to practice medicine in all |
|
| | HB3721 | - 53 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | of its branches. |
2 | | (jj) "Poppy straw" means all parts, except the seeds, of |
3 | | the opium
poppy, after mowing.
|
4 | | (kk) "Practitioner" means a physician licensed to practice |
5 | | medicine in all
its branches, dentist, optometrist, podiatric |
6 | | physician,
naturopathic physician, veterinarian, scientific |
7 | | investigator, pharmacist, physician assistant,
advanced |
8 | | practice registered nurse,
licensed practical
nurse, |
9 | | registered nurse, emergency medical services personnel, |
10 | | hospital, laboratory, or pharmacy, or other
person licensed, |
11 | | registered, or otherwise lawfully permitted by the
United |
12 | | States or this State to distribute, dispense, conduct research
|
13 | | with respect to, administer or use in teaching or chemical |
14 | | analysis, a
controlled substance in the course of professional |
15 | | practice or research.
|
16 | | (ll) "Pre-printed prescription" means a written |
17 | | prescription upon which
the designated drug has been indicated |
18 | | prior to the time of issuance; the term does not mean a written |
19 | | prescription that is individually generated by machine or |
20 | | computer in the prescriber's office.
|
21 | | (mm) "Prescriber" means a physician licensed to practice |
22 | | medicine in all
its branches, dentist, optometrist, |
23 | | prescribing psychologist licensed under Section 4.2 of the |
24 | | Clinical Psychologist Licensing Act with prescriptive |
25 | | authority delegated under Section 4.3 of the Clinical |
26 | | Psychologist Licensing Act, podiatric physician, naturopathic |
|
| | HB3721 | - 54 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | physician, or
veterinarian who issues a prescription, a |
2 | | physician assistant who
issues a
prescription for a controlled |
3 | | substance
in accordance
with Section 303.05, a written |
4 | | delegation, and a written collaborative agreement required |
5 | | under Section 7.5
of the
Physician Assistant Practice Act of |
6 | | 1987, an advanced practice registered
nurse with prescriptive |
7 | | authority delegated under Section 65-40 of the Nurse Practice |
8 | | Act and in accordance with Section 303.05, a written |
9 | | delegation,
and a written
collaborative agreement under |
10 | | Section 65-35 of the Nurse Practice Act, an advanced practice |
11 | | registered nurse certified as a nurse practitioner, nurse |
12 | | midwife, or clinical nurse specialist who has been granted |
13 | | authority to prescribe by a hospital affiliate in accordance |
14 | | with Section 65-45 of the Nurse Practice Act and in accordance |
15 | | with Section 303.05, or an advanced practice registered nurse |
16 | | certified as a nurse practitioner, nurse midwife, or clinical |
17 | | nurse specialist who has full practice authority pursuant to |
18 | | Section 65-43 of the Nurse Practice Act.
|
19 | | (nn) "Prescription" means a written, facsimile, or oral |
20 | | order, or an electronic order that complies with applicable |
21 | | federal requirements,
of
a physician licensed to practice |
22 | | medicine in all its branches,
dentist, podiatric physician ,
|
23 | | naturopathic physician, or veterinarian for any controlled
|
24 | | substance, of an optometrist in accordance with Section 15.1 |
25 | | of the Illinois Optometric Practice Act of 1987, of a |
26 | | prescribing psychologist licensed under Section 4.2 of the |
|
| | HB3721 | - 55 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | Clinical Psychologist Licensing Act with prescriptive |
2 | | authority delegated under Section 4.3 of the Clinical |
3 | | Psychologist Licensing Act, of a physician assistant for a
|
4 | | controlled substance
in accordance with Section 303.05, a |
5 | | written delegation, and a written collaborative agreement |
6 | | required under
Section 7.5 of the
Physician Assistant Practice |
7 | | Act of 1987, of an advanced practice registered
nurse with |
8 | | prescriptive authority delegated under Section 65-40 of the |
9 | | Nurse Practice Act who issues a prescription for a
controlled |
10 | | substance in accordance
with
Section 303.05, a written |
11 | | delegation, and a written collaborative agreement under |
12 | | Section 65-35 of the Nurse Practice Act, of an advanced |
13 | | practice registered nurse certified as a nurse practitioner, |
14 | | nurse midwife, or clinical nurse specialist who has been |
15 | | granted authority to prescribe by a hospital affiliate in |
16 | | accordance with Section 65-45 of the Nurse Practice Act and in |
17 | | accordance with Section 303.05 when required by law, or of an |
18 | | advanced practice registered nurse certified as a nurse |
19 | | practitioner, nurse midwife, or clinical nurse specialist who |
20 | | has full practice authority pursuant to Section 65-43 of the |
21 | | Nurse Practice Act.
|
22 | | (nn-5) "Prescription Information Library" (PIL) means an |
23 | | electronic library that contains reported controlled substance |
24 | | data. |
25 | | (nn-10) "Prescription Monitoring Program" (PMP) means the |
26 | | entity that collects, tracks, and stores reported data on |
|
| | HB3721 | - 56 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | controlled substances and select drugs pursuant to Section |
2 | | 316. |
3 | | (oo) "Production" or "produce" means manufacture, |
4 | | planting,
cultivating, growing, or harvesting of a controlled |
5 | | substance other than methamphetamine.
|
6 | | (pp) "Registrant" means every person who is required to |
7 | | register
under Section 302 of this Act.
|
8 | | (qq) "Registry number" means the number assigned to each |
9 | | person
authorized to handle controlled substances under the |
10 | | laws of the United
States and of this State.
|
11 | | (qq-5) "Secretary" means, as the context requires, either |
12 | | the Secretary of the Department or the Secretary of the |
13 | | Department of Financial and Professional Regulation, and the |
14 | | Secretary's designated agents. |
15 | | (rr) "State" includes the State of Illinois and any state, |
16 | | district,
commonwealth, territory, insular possession thereof, |
17 | | and any area
subject to the legal authority of the United |
18 | | States of America.
|
19 | | (rr-5) "Stimulant" means any drug that (i) causes an |
20 | | overall excitation of central nervous system functions, (ii) |
21 | | causes impaired consciousness and awareness, and (iii) can be |
22 | | habit-forming or lead to a substance abuse problem, including, |
23 | | but not limited to, amphetamines and their analogs, |
24 | | methylphenidate and its analogs, cocaine, and phencyclidine |
25 | | and its analogs. |
26 | | (rr-10) "Synthetic drug" includes, but is not limited to, |
|
| | HB3721 | - 57 - | LRB103 30237 AMQ 56665 b |
|
|
1 | | any synthetic cannabinoids or piperazines or any synthetic |
2 | | cathinones as provided for in Schedule I. |
3 | | (ss) "Ultimate user" means a person who lawfully possesses |
4 | | a
controlled substance for his or her own use or for the use of |
5 | | a member of his or her
household or for administering to an |
6 | | animal owned by him or her or by a member
of his or her |
7 | | household.
|
8 | | (Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22; |
9 | | 102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)
|
10 | | Section 999. Effective date. This Act takes effect upon |
11 | | becoming law.
|